Recro Pharma, Inc. (REPH) Reaches $8.30 Formed H&S; Last Week Trinseo S.A. (TSE) Coverage

Recro Pharma, Inc. (REPH) formed H&S with $7.55 target or 9.00% below today’s $8.30 share price. Recro Pharma, Inc. (REPH) has $158.76 million valuation. The stock decreased 4.49% or $0.39 during the last trading session, reaching $8.3. About 122,379 shares traded or 3.94% up from the average. Recro Pharma, Inc. (NASDAQ:REPH) has risen 26.61% since February 3, 2017 and is uptrending. It has outperformed by 9.91% the S&P500.

Among 6 analysts covering Trinseo (NYSE:TSE), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Trinseo had 24 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Barclays Capital with “Equal-Weight” on Tuesday, November 7. On Monday, November 6 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Citigroup with “Neutral” on Thursday, August 4. The firm has “Buy” rating by Jefferies given on Friday, March 31. As per Wednesday, January 17, the company rating was maintained by Wells Fargo. The firm has “Buy” rating by Alembic given on Wednesday, August 2. The firm has “Equal Weight” rating given on Friday, August 7 by Barclays Capital. The company was maintained on Wednesday, July 12 by Citigroup. On Thursday, February 1 the stock rating was maintained by Barclays Capital with “Equal-Weight”. The firm has “Buy” rating given on Thursday, August 6 by Zacks. See Trinseo S.A. (NYSE:TSE) latest ratings:

01/02/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Equal-Weight Old Target: $78 New Target: $85 Maintain
17/01/2018 Broker: Wells Fargo Rating: Buy New Target: $84.0 Maintain
12/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $92.0
11/12/2017 Broker: Alembic Rating: Buy Maintain
07/11/2017 Broker: Barclays Capital Rating: Equal-Weight Old Target: $73 New Target: $78 Maintain
06/11/2017 Broker: Jefferies Rating: Buy New Target: $85.0 Maintain
12/10/2017 Broker: Alembic Rating: Buy New Target: $80.0 Maintain
06/10/2017 Broker: Jefferies Rating: Buy New Target: $82.0 Maintain
05/09/2017 Broker: Alembic Rating: Buy Maintain
28/08/2017 Broker: Jefferies Rating: Buy New Target: $82.0 Maintain

Among 8 analysts covering Recro Pharma (NASDAQ:REPH), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Recro Pharma had 14 analyst reports since August 25, 2015 according to SRatingsIntel. The company was initiated on Friday, September 16 by Roth Capital. H.C. Wainwright initiated it with “Buy” rating and $19 target in Wednesday, September 2 report. Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) on Thursday, July 20 with “Buy” rating. The rating was upgraded by Zacks on Tuesday, August 25 to “Hold”. Roth Capital maintained Recro Pharma, Inc. (NASDAQ:REPH) on Thursday, November 9 with “Buy” rating. The rating was maintained by Piper Jaffray with “Buy” on Tuesday, July 25. The stock has “Overweight” rating by Piper Jaffray on Monday, December 19. The rating was initiated by Brean Capital with “Buy” on Monday, October 3. The firm earned “Buy” rating on Monday, July 31 by Roth Capital. The firm has “Buy” rating given on Friday, September 16 by TH Capital.

Analysts await Recro Pharma, Inc. (NASDAQ:REPH) to report earnings on March, 5. They expect $-0.78 EPS, up 3.70% or $0.03 from last year’s $-0.81 per share. After $-0.48 actual EPS reported by Recro Pharma, Inc. for the previous quarter, Wall Street now forecasts 62.50% negative EPS growth.

Since December 12, 2017, it had 0 insider purchases, and 5 insider sales for $1.43 million activity. 38,810 Recro Pharma, Inc. (NASDAQ:REPH) shares with value of $344,688 were sold by SCP Vitalife Partners II LP. Broadfin Healthcare Master Fund Ltd had sold 93,237 shares worth $919,128. $13,956 worth of Recro Pharma, Inc. (NASDAQ:REPH) shares were sold by SCP Vitalife Partners (Israel) II – L.P..

Investors sentiment decreased to 1.65 in 2017 Q3. Its down 0.56, from 2.21 in 2017Q2. It dived, as 7 investors sold Recro Pharma, Inc. shares while 10 reduced holdings. 5 funds opened positions while 23 raised stakes. 9.63 million shares or 4.72% less from 10.10 million shares in 2017Q2 were reported. Barclays Public Ltd holds 590 shares or 0% of its portfolio. Alyeska Investment Grp Lp holds 906,398 shares. Manufacturers Life Com The owns 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 140 shares. Vanguard Gp has 0% invested in Recro Pharma, Inc. (NASDAQ:REPH) for 666,252 shares. 50,000 were accumulated by Bb&T Corp. Dimensional Fund Advisors Lp stated it has 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Janney Montgomery Scott Ltd Limited Liability Company invested in 0% or 16,485 shares. Cadence Capital Mgmt Ltd Liability Co holds 0.09% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH) for 167,637 shares. Tiaa Cref Invest Mngmt Ltd reported 0% of its portfolio in Recro Pharma, Inc. (NASDAQ:REPH). Strs Ohio holds 4,000 shares. Nationwide Fund Advsrs accumulated 7,576 shares. Granite Point Cap Lp accumulated 38,000 shares or 0.07% of the stock. 141,841 are owned by Northern Trust. Massachusetts-based Panagora Asset Mgmt Inc has invested 0% in Recro Pharma, Inc. (NASDAQ:REPH). New York State Common Retirement Fund holds 0% or 1,800 shares in its portfolio.